Abstract:Background & Aims Bulevirtide (BLV) is a first-in-class entry inhibitor and the only approved treatment for patients chronically infected with HDV in Europe. We aimed to investigate the efficacy of BLV treatment in paired liver biopsies obtained at baseline and after 24 or 48 weeks of treatment. Methods We performed a combined analysis of 126 paired liver biopsies derived from 3 clinical trials. In the phase 2 clinical trial MYR202, patients with chronic hepatitis D were randomised to receive 24 weeks of BLV at 2mg, 5mg or 10mg/day. Patients in MYR203 (phase 2) and MYR301 (phase 3) received 48 weeks of 2mg or 10mg/day BLV. Tenofovir disoproxil fumarate monotherapy or delayed treatment served as comparator. Virological parameters and infection-related host genes were assessed by qPCR and immunohistochemistry. Results At week 24, median intrahepatic HDV RNA decline from baseline was 0.9Log10 with 2mg (n=7), 1.1Log10 with 5mg (n=5) and 1.4Log10 with 10mg (n=7). At week 48, median reductions were 2.2Log10 with 2mg (n=27) and 2.7Log10 with 10mg (n=37), while HDV RNA levels did not change in the comparator arms. Notably, a drastic decline in the number of hepatitis delta antigen positive hepatocytes and a concomitant decrease of transcriptional levels of inflammatory chemokines and interferon-stimulated genes was determined in all BLV-treatment arms. Despite the abundance of HBsAg-positive hepatocytes, replication and covalently closed circular DNA (cccDNA) levels of the helper virus HBV were low and remained unaffected by BLV treatment. Conclusion Blocking viral entry diminishes signs of liver inflammation and promotes a strong reduction of HDV infection within the liver, thus suggesting that some patients may achieve HDV cure with long-term treatment. Impact and implications Chronic infection with the hepatitis delta virus causes the most severe form of viral hepatitis affecting approximately 12 million people worldwide. The entry inhibitor bulevirtide (BLV) is the only recently approved anti-HDV drug, which has proven efficacious and safe in clinical trials and real-word data. Here, we investigated paired liver biopsies at baseline and after 24 or 48 weeks of treatment from three clinical trials to understand the effect of the drug on viral and host parameters in the liver, the site of viral replication. We found that BLV treatment strongly reduces the number of HDV-infected cells and signs of liver inflammation. This data implies that blocking viral entry ameliorates liver inflammation and that prolonged treatment regimens might lead to HDV cure in some patients. This concept will inform further developments of therapeutic strategies and combination treatments in CHD patients.

Kinetics of the three HBsAg forms along with HDV-RNA predict virological and biochemical responses in chronic hepatitis delta patients treated with bulevirtide for 48 weeks

HBcrAg and Pg RNA and the Therapeutic Effect in HBeAg‐positive Patients Receiving Anti‐viral Therapy, Baseline Serum HBV‐RNA is a Powerful Predictor of Response

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

Complementarity-Determining Region 3 Size Spectratypes of T Cell Receptor Β Chains in CD8 + T Cells Following Antiviral Treatment of Chronic Hepatitis B

Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 96 weeks: a retrospective multicenter european study (SAVE-D)

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial

Improvement of non-invasive fibrosis tests in HDV cirrhotic patients with clinically significant portal hypertension responding to Bulevirtide monotherapy

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy

Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA

Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D

Early Serum Hepatitis B Virus Large Surface Protein Level: A Stronger Predictor of Virological Response to Peginterferon Alfa-2A Than That to Entecavir in HBeAg-positive Patients with Chronic Hepatitis B